Clinical trial · Interventional
Cost-Effectiveness Study of PEG-rhG-CSF in Prophylactic Treatment of Neutropenia After Chemotherapy in Lymphoma
Cost-Effectiveness Study of Pegylated Recombinant Human Granulocyte Colony-stimulating Factor(PEG-rhG-CSF) in Prophylactic Treatment of Neutropenia After Chemotherapy in Lymphoma
NCT04083079CI-TRIAL-00040501unknownPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a pharmacoeconomic research to explore the cost-effectiveness of PEG-rhG-CSF and rhG-CSF in prophylactic treatment of neutropenia in lymphoma patients. It should provide more scientific basis for clinical decision-making.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cost-Benefit Analysis | — | UNRESOLVED | — |
| Granulocyte Colony-Stimulating Factor | — | UNRESOLVED | — |
| Lymphoma, Non-Hodgkin | Non-Hodgkin Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| PEG-rhG-CSF | Drug | — | UNRESOLVED |
| rhG-CSF | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- PEG-rhG-CSF cohort
- description
- PEG-rhG-CSF primary/secondary prevention will be given 24-72 hours after each cycle for only once. Dosage: 6mg for weight ≥45kg，3mg for weight \<45kg, subcutaneous injection
- interventionNames
- Drug: PEG-rhG-CSF
- type
- EXPERIMENTAL
- label
- rhG-CSF cohort
- description
- rhG-CSF primary/secondary prevention will be given 24-72 hours after each cycle until absolute neutrophil count ≥2×10\^9/L. rhG-CSF treatment will be given when there is neutropenia until absolute neutrophil count ≥2×10\^9/L. Dosage: 5μg/kg/d, subcutaneous injection
- interventionNames
- Drug: rhG-CSF
Primary outcomes (1)
- measure
- Incremental Cost-Effectiveness ratio
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * 18-65 years * histologically confirmed de novo Non Hodgkin's lymphoma (except highly aggressive lymphoma such as lymphoblastic lymphoma and Burkitt lymphoma) * plan to be given 6-8 cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) ± Rituximab (R) * KPS ≥70 * plan continuous PEG-rhG-CSF or rhG-CSF adiministration after at least 3 cycles of treatment for neutropenia prophylactic treatment * absolute neutrophil count≥1.5×109/L，platelet count ≥100× 109/L，hemoglobin≥90g/L，while blood cell count≥3.0×109/L，without bleeding signs * adquate liver and renal function as protocol discribed * no serious cardiovascular disease as protocol discribed * under good mental conditions and informed consented * potential benefit for subjects based on investigators' decision Exclusion Criteria: * history of hematopoetic stem cell transplantationor organ transplantation * uncontrollable infection * allergic to study drugs or ingredients * accepted any other investigational drug or participated another interventional study within 30 days during screening period * other uncontrollable conditions judged by the investigator * breast-feeding , pregnant or plan to be pregnant during study observation period
References
Publications (0)
Data not yet available
No reference posted for this study.